The Utility Of Secretagogin As A Novel Marker For The Diagnosis Of Lung Neuroendocrine Carcinoma

SCGN had the lowest sensitivity (55%) among the markers. However, it performed better than chromogranin A (71% versus 68%) in the diagnosis of SCLCs and c-SCLCs. Its positive tumor cell percentage was significantly higher than chromogranin A in SCLCs and c-SCLCs (18% higher, P=0.0054). The above data showed that SCGN could be used as a supplemental neuroendocrine marker to diagnose small cell carcinoma.